IL317254A - Method for producing recombinant aav particles - Google Patents

Method for producing recombinant aav particles

Info

Publication number
IL317254A
IL317254A IL317254A IL31725424A IL317254A IL 317254 A IL317254 A IL 317254A IL 317254 A IL317254 A IL 317254A IL 31725424 A IL31725424 A IL 31725424A IL 317254 A IL317254 A IL 317254A
Authority
IL
Israel
Prior art keywords
recombinant aav
producing recombinant
aav particles
particles
producing
Prior art date
Application number
IL317254A
Other languages
Hebrew (he)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of IL317254A publication Critical patent/IL317254A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
IL317254A 2022-07-14 2023-07-12 Method for producing recombinant aav particles IL317254A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22184964 2022-07-14
PCT/EP2023/069338 WO2024013239A1 (en) 2022-07-14 2023-07-12 Method for producing recombinant aav particles

Publications (1)

Publication Number Publication Date
IL317254A true IL317254A (en) 2025-01-01

Family

ID=82799885

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317254A IL317254A (en) 2022-07-14 2023-07-12 Method for producing recombinant aav particles

Country Status (12)

Country Link
US (1) US20250263746A1 (en)
EP (1) EP4554604A1 (en)
JP (1) JP2025524619A (en)
KR (1) KR20250036743A (en)
CN (1) CN119546320A (en)
AR (1) AR129895A1 (en)
AU (1) AU2023305838A1 (en)
CA (1) CA3261054A1 (en)
IL (1) IL317254A (en)
MX (1) MX2025000378A (en)
TW (1) TW202417619A (en)
WO (1) WO2024013239A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120399044B (en) * 2025-04-30 2026-04-03 尚纯生物科技(武汉)有限公司 A nanobody that specifically binds to AAV2 and its application

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US6093699A (en) 1987-07-09 2000-07-25 The University Of Manitoba Method for gene therapy involving suppression of an immune response
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1994017810A1 (en) 1993-02-12 1994-08-18 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1994023744A1 (en) 1993-04-16 1994-10-27 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6100242A (en) 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6004797A (en) 1995-11-09 1999-12-21 Avigen, Inc. Adenovirus helper-free recombinant AAV Virion production
US6228646B1 (en) 1996-03-07 2001-05-08 The Regents Of The University Of California Helper-free, totally defective adenovirus for gene therapy
DE19955558C2 (en) 1999-11-18 2003-03-20 Stefan Kochanek Permanent amniocyte cell line, its production and use for the production of gene transfer vectors
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
JP4559429B2 (en) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション Method for producing a recombinant AAV virion preparation substantially free of empty capsids
DE102005054628A1 (en) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Process for the preparation of permanent human cell lines
EP2529020B1 (en) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
EP3795581A3 (en) 2011-08-24 2021-06-09 The Board of Trustees of the Leland Stanford Junior University New avv capsid proteins for nucleic acid transfer
JP6342886B2 (en) 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Composition and method for highly efficient gene transfer using AAV capsid variants
NZ716102A (en) 2013-07-22 2021-12-24 The Children’S Hospital Of Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3384015A4 (en) 2015-12-01 2019-05-29 Spark Therapeutics, Inc. Scalable methods for producing recombinant adeno-associated viral (aav) vector in serum-free suspension cell culture system suitable for clinical use
WO2018226887A1 (en) 2017-06-07 2018-12-13 Spark Therapeutics, Inc. ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION
EP3658250A4 (en) 2017-06-30 2021-10-27 Spark Therapeutics, Inc. AAV VECTOR COLUMN PURIFICATION METHOD
EP4175969A4 (en) 2020-07-01 2024-07-24 Medimmune, LLC CLEANING AGENTS AND METHOD FOR CLEANING A BIOTHERAPEUTIC PRODUCT

Also Published As

Publication number Publication date
CA3261054A1 (en) 2024-01-18
WO2024013239A1 (en) 2024-01-18
KR20250036743A (en) 2025-03-14
CN119546320A (en) 2025-02-28
US20250263746A1 (en) 2025-08-21
MX2025000378A (en) 2025-02-10
AU2023305838A1 (en) 2024-11-28
AR129895A1 (en) 2024-10-09
JP2025524619A (en) 2025-07-30
EP4554604A1 (en) 2025-05-21
TW202417619A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
ZA202210745B (en) Method for the production of aav
IL284532A (en) Methods and systems for producing aav particles
IL304620A (en) Method for purifying recombinant viral particles
EP3918792A4 (en) Method and apparatus for improved sub-block partitioning intra sub-partitions coding mode
EP3909241A4 (en) System and method for improving combined inter and intra prediction
IL320190A (en) Method of purifying full recombinant aav particles
PL4134411T3 (en) Method for modifying mineral raw material
PH12021551680A1 (en) Improved method for producing high purity lead
EP4023661A4 (en) Method for producing peptide compound
EP3939959A4 (en) Method for producing peptide compound
EP3922638A4 (en) Method for producing peptide compound
IL287063A (en) Method for producing biotissue-like structure
GB202000903D0 (en) Process for producing cardiomyocytes
EP4169938A4 (en) Method for purifying recombinant protein
GB202019455D0 (en) Method for producing virus
SG11202107201YA (en) Process for producing, isolating, and purifying modified recombinant proteins
HK40104539A (en) Method for purifying recombinant viral particles
HUE072417T2 (en) New systems for producing recombinant proteins
IL319976A (en) Method for producing glycoprotein compositions
CA3285455A1 (en) Method for the production of recombinant aav particle preparations
IL320073A (en) Method for increasing recombinant protein expression
AU2022901541A0 (en) Methods for producing polypeptide variants
CA3278288A1 (en) Method for glycoprotein modification
HK40049499A (en) Scalable method for recombinant aav production
EP4257267A4 (en) Method for producing aluminum-containing particles